Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Vynmac Listing OK’ed, but Chuikyo Urges Response to Market Expansion with Similar Upgrade
November 18, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- MHLW Panel to Discuss Idorsia’s Cerebral Vasospasm Drug on Nov. 26; Efient Up for Review Again
November 17, 2021
- Sclerosing Cholangitis Added to ADR List in Tecentriq Label
November 17, 2021
- MSD’s Noxafil Price to Be Trimmed 0.5% under CEA Scheme
November 17, 2021
- Takeda’s Cell Therapy Alofisel Gets 5.62 Million Yen Price Tag
November 17, 2021
- 50 Billion Yen-Plus Peak Sales Projected for Pfizer’s Vynmac, Listing Set for Nov. 25
November 17, 2021
- Japan Panel Agrees to Give Free “Catch-Up” HPV Shots
November 16, 2021
- Chuikyo Subcommittee OKs Basic SaMD Reimbursement Rule
November 16, 2021
- PMDA’s SaMD Consultation Desk Handling 30 Inquiries per Month
November 16, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- Pharma Calls for Enhancing Pre-Analysis Discussions in CEA Scheme: Chuikyo
November 15, 2021
- Japan to Reinstate HPV Vaccine Recommendation after 8 Years in Limbo
November 15, 2021
- Govt to Provide Up to 2 Billion Yen per Oral COVID-19 Drug to Support Development
November 15, 2021
- Hidemichi Sato Appointed as New Senior Vice Health Minister
November 12, 2021
- MSD’s Antifungal Drug Noxafil in for Price Cuts as Chuikyo OKs CEA Results
November 11, 2021
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…